RxDoctor Payments Data
★ My doctorsLook up a doctor →

Gary Newsom

Tuscaloosa, ALNPI 1992723019

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $48,720 of the $51,106 with a category attached, or 95.3%. AbbVie accounts for 97.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $15,713 and has fallen 97.8% since, to $339 in 2025.

$51,106in general payments, 2019–2025

Across 128 payments — averaging $399.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$50K
  • Alkermes, Inc.$259
  • Johnson & Johnson$259
  • Otsuka America Pharmaceutical, Inc.$248
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$185
  • Teva Pharmaceuticals USA, Inc.$162
  • plus $277 from 7 others

What the payments were for

  • Speaking & faculty fees$48,72095%
  • Travel & lodging$3771%
  • Food & beverage$2,0094%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)65$49,715
Alkermes, Inc.13$259
Johnson & Johnson13$259
Otsuka America Pharmaceutical, Inc.8$248
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)4$185
Teva Pharmaceuticals USA, Inc.10$162
Lundbeck LLC7$144
Almatica Pharma LLC3$43
Bioxcel Therapeutics, Inc.1$23
Alfasigma USA, Inc.1$21
Neurocrine Biosciences, Inc.1$18
Axsome Therapeutics, Inc.1$15
Takeda Pharmaceuticals U.S.A., Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Where these figures come from

Is this you, or does something look wrong? →